Vol. 22/No. 02 | OncologyLive

Systemic Treatment Options Expand in Nonmetastatic NSCLC

February 05, 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

February 02, 2021

Investigators are seeking to determine whether amcenestrant can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer.

RET Joins the Ranks of Actionable Targets in Precision Oncology

February 01, 2021

Pathways

Over the past 2 decades, a growing number of targetable tumor-specific molecular alterations have been identified, ushering in the era of precision oncology. Now, alterations in the RET gene can be added to the list of druggable targets.

Real-World Data Grow Increasingly Relevant in Oncology Practice

January 27, 2021

The importance of objectively valid data is well established in clinical medicine. Such data include an accurate recording of a patient’s clinical history; evaluation of signs and symptoms of illness; and measurement of various routine indicators, such as granulocyte and platelet counts, serum glucose, electrolytes, and liver function tests.

Rugo Sets the Stage for a Busy Year in Breast Cancer

January 25, 2021

Hope S. Rugo, MD, FASCO, describes her work in medical oncology, previews the upcoming Miami Breast Cancer Conference, and speaks to what she is looking forward to in 2021 with regard to breast cancer treatment.

Pharma Innovation Is Saving the World

January 18, 2021

Before New Year’s Day, millions of Americans had received the coronavirus disease 2019 vaccine, including frontline physicians and health care providers and nursing home patients, our most vulnerable citizens.